Digi International Launches Digi WAN Bonding, Delivering Bonded Gigabit Internet Speeds and Improved Connection Reliability
Digi International (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, today announced the release of its latest value-added service — Digi WAN Bonding — to deliver true Gigabit speeds for dramatically enhanced network performance. This solution, which is fully integrated into the Digi technology stack, also dramatically improves Internet reliability and increases bandwidth for customers in the enterprise, industrial and transportation sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418006030/en/
Digi International Launches Digi WAN Bonding, Delivering Bonded Gigabit Internet Speeds and Improved Connection Reliability (Graphic: Business Wire)
Available as an add-on value-added service to the industry-leading IoT device and network management platform, Digi Remote Manager® (Digi RM), Digi WAN Bonding leverages the edge intelligence of Digi Accelerated Linux (DAL) OS, Digi’s powerful Linux-based operating system. Digi WAN Bonding enables customers running DAL OS on their Digi devices to centrally configure, deploy, and manage the bonding together of multiple WAN connections. This WAN aggregation provides a sophisticated blend of increased throughput speeds, WAN smoothing, packet redundancy, and seamless failover for always-on Internet connectivity.
Digi WAN Bonding yields four key benefits:
- Increased bandwidth: By combining multiple connections, WAN bonding can provide a higher total bandwidth than any single connection for video streaming or file sharing.
- Increased speed: Additionally, combining multiple WAN links supports increased speed for one or multiple devices, up to 1 Gbps maximum.
- Improved reliability: WAN bonding also improves the reliability of your bonded communication channels. If a connection fails, the others continue to provide service.
- Reduced costs: WAN bonding can also reduce costs, for example enabling enterprises to obtain lower monthly rates for multiple connections.
Improved network performance is of extreme benefit to organizations requiring excellent speed and resiliency for data-intensive applications. These include video streaming to multiple media displays, vehicle cameras, and video conferencing. By providing customers with hot failover protection, this service ensures that if one WAN connection fails, the other connection takes over, thereby minimizing network downtime. Digi WAN Bonding also allows companies to take advantage of multiple ISPs, which can result in cost savings when businesses can negotiate better pricing and/or secure a provider that offers the best value for their specific needs.
“Organizations the world over are constantly searching for ways to boost network speed and reliability,” said Kinana Hussain, Vice President of Product Management for Digi International. “By fully integrating bandwidth bonding technology with Digi’s DAL OS and Digi Remote Manager, we’re able to provide businesses that rely on their network for critical operations with ultra-fast, ultra-reliable network performance and cost-efficient connectivity they very much want and need.”
Digi WAN Bonding — developed in collaboration with Bondix Intelligence — is distinct in that it allows for a maximum throughput speed of up to one Gigabit per second, compared to max speeds of 200 Mbps from other WAN bonding services.
“At Bondix, we’ve been thrilled to partner with Digi on rolling out our Bondix S.A.NE technology as an add-on service to Digi Remote Manager,” said Martin Santner, Director of Sales and Business Development for Bondix Intelligence. “This collaboration simplifies WAN aggregation, putting the mission-critical capabilities of WAN bonding into the hands of those who need it, enabling them to offer faster, better, more reliable connectivity when and where it matters.”
S.A.NE, which is short for Simple Aggregation of Networks, is proprietary software engineered by Bondix Technology to ensure reliable voice, video, and data transmission connectivity for mobile and stationary deployments alike.
For more information, visit https://www.digi.com/products/iot-software-services/digi-wan-bonding.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006030/en/
Contact information
Media Contact:
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom